Trace Neuroscience has launched its clinical development program for TRCN-1023, an experimental treatment for amyotrophic lateral sclerosis (ALS) that is designed to restore the function of UNC13A, a protein involved in nerve-muscle communication. The global clinical program includes FUNCTION ALS, a company-sponsored Phase 1/2 clinical trial authorized…
Discussion
I’m writing this column from vacation in a place I once traveled with my late husband, Jeff, long before he was diagnosed with ALS in 2018. It was a dream trip of his, and we went together for his birthday more than a decade ago. On this trip, we…
Discussion
The lowest tested dose of Amylyx Pharmaceuticals‘ treatment candidate AMX0114 was found to be safe and well tolerated among people with amyotrophic lateral sclerosis (ALS) in an ongoing Phase 1 clinical trial. Biomarkers of nerve damage due to ALS remained relatively stable from the study’s start — a result…
Discussion
A couple months ago, I planted zinnia and strawflower seeds in two plastic bins and set them in the sunlight under our patio window in my dining room. I’ve grown vegetables from seeds in the past, but never flowers. Vegetables feel practical because food is necessary to sustain life, while…
Discussion
The first patient has been dosed in a Phase 1/2 clinical trial evaluating Leal Therapeutics‘ LTX-002, an antisense oligonucleotide designed to target abnormalities in fat metabolism that may contribute to amyotrophic lateral sclerosis (ALS). The NeurALS trial (NCT07660614) is now recruiting an estimated 56 adults with ALS at…
Discussion
Nura Bio has raised $73.8 million to support two experimental therapies designed to protect nerve cells from damage, including one that is already being tested in people with amyotrophic lateral sclerosis (ALS). Proceeds from the Series B financing round, usually the second major funding round for…
Discussion
Treatment burden — the workload associated with managing a disease, including taking medications, attending medical appointments, and carrying out self-care tasks — was reported by nearly 70% of patients with amyotrophic lateral sclerosis (ALS), according to a study in Italy. Among patients reporting any burden, more than half were…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Becoming educated and informed about ALS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ALS journey.
There is no cure for ALS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
